Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: opalapril who wrote (2547)	1/12/2001 10:35:00 AM
From: aknahow	Respond to of 52153

FYI links to abstracts from Wall Street Transcripts. The Wall Street Transcript Newsletter ------------------------------------------- ========== New and Free from TWST =========== The Wall Street Transcript and Alerts.com now give you the power to track your favorite stock(s) and sectors. Simply go to twst.com and enter the stock tickers and keywords you want to follow. You will receive emails with links directly to the articles when TWST publishes an article with the tickers or keywords you select. Alerts.com's technology also allows you to receive these free alerts on your wireless devices! Go to twst.com Get the information you need - where, when and how you want it. =========================================== -- In our interview with Pharsight Corporation, the CEO discusses the company's plans for partnerships. He claims, "We are working on some very significant partnerships now" and "We are also working to establish relationships, with, for example, some large consulting organizations that operate in related areas to ours and with whom we think there could be some mutual advantage." To read on Pharsight's future plans, click on twst.com. -- In our interview with PRAECIS PHARMACEUTICALS, the CEO discusses the company's greatest opportunities. He states, "There doesn't seem to be any end to how much more information - faster, better, cheaper - one can deliver with technology that consumers or the market will absorb" and he claims the greatest opportunity for the future market is new drugs. The CEO also discusses their partnership with Amgen. To read the full interview excerpt, please click on twst.com. -- In another interview, the CEO of Packard BioScience discusses "exciting growth developments within the drug screening area." These growth developments are a result of "increased demands placed on the pharmaceutical companies to do screening more efficiently and for less money." To find out how Packard BioScience plans on dealing with this situation, click on twst.com. -- All these extracts below are free, but if you want the full text to any of these articles, call (212) 952 7433, or go to twst.com Following are the latest interviews from the the Healthcare Sector published by The Wall Street Transcript. ______________ Drugs & Biotech CEO comments on Gene Logic's financial situation archive.twst.com CEO explains how Gemini Genomics differentiates itself from other people who are doing parallel things archive.twst.com CEO reports on Genaissance Pharmaceuticals' partnership with Janssen Research Foundation archive.twst.com President talks about the benchmarks investors should use to judge Genzyme Biosurgery's progress archive.twst.com CEO reports on Human Genome Sciences' competitive edge archive.twst.com Senior Vice President reports on Inspire Pharmaceuticals' hybrid strategy regarding the commercialization of its technology archive.twst.com Senior Vice President explains HCA—The Healthcare Company's “patients first” philosophy archive.twst.com Genzyme's CEO believes that Renagel will be the growth driver for the company in the next few years archive.twst.com CEO outlines Pharsight's plans for potential partnerships archive.twst.com President is proud of Caremark Rx' financial ratios archive.twst.com CEO looks at the competition for Angiotech Pharmaceuticals archive.twst.com CollaGenex Pharmaceuticals' CEO reports on the market size for a product like Periostat archive.twst.com CEO of Albany Molecular Research believes that there is an increased need to outsource in pharma R&D archive.twst.com Chronimed's focus is on providing mail order and retail-based pharmacies, reports CEO archive.twst.com CEO points to the single best opportunity in the near future for First Horizon Pharmaceutical archive.twst.com CEO comments on the competitive landscape for SpectRx archive.twst.com EPIX Medical is planning on focusing solely on research and development, states CEO archive.twst.com Valentis' goal is to continue to have the broadest array of delivery technologies for biopharmaceuticals in the industry, reports archive.twst.com Medarex will continue to look for opportunities to acquire complementary technologies, reports CEO archive.twst.com Matrix Pharmaceutical's CEO is very excited about the commercial potential of IntraDose archive.twst.com CEO reports on Large Scale Biology's good track record with both organic growth and acquisitions archive.twst.com CEO explains why AtheroGenics' R&D expenditures for the next year may increase archive.twst.com CEO commends both the management team and the scientific team at Vion Pharmaceuticals archive.twst.com CEO looks at the competition for MedQuist archive.twst.com CEO comments on MediChem’s current stock price archive.twst.com CEO gives an assessment of The Medicines Company's management team archive.twst.com CEO outlines QIAGEN's sales and marketing strategies archive.twst.com CEO believes that Molecular Devices can continue to expand its lead in providing innovative technology for drug discovery research archive.twst.com CEO discusses the size and growth potential of the markets for Diversa Corporation archive.twst.com CEO praises Vertex Pharmaceuticals' scientific and business team archive.twst.com CEO looks at the competitive advantages for DIANON Systems archive.twst.com CEO commends Discovery Partners International's management team archive.twst.com Pharsight will focus on establishing its information products business, reports CEO archive.twst.com CEO outlines the competitive environment for Esperion Therapeutics archive.twst.com CEO comments on PAREXEL International's current stock price archive.twst.com CEO of Medicis Pharmaceutical speaks about the trends in cosmetic dermatology archive.twst.com CEO points to the greatest opportunities for Biacore over the next several years archive.twst.com CEO reports on Celgene's objective to build a major integrated pharmaceutical company focused on cancer and immunology archive.twst.com Tularik's goal is to submit one to two IND applications per year, reports CEO archive.twst.com CEO highlights Genomic Solutions’ competitive advantages archive.twst.com CEO comments on Amylin Pharmaceuticals' top management team archive.twst.com CEO outlines Versicor's product line archive.twst.com CEO reports on the management team at Versicos archive.twst.com CEO speaks about Neose Technologies' co-development enterprise archive.twst.com Neose Technologies aims to remain in the absolute forefront of carbohydrate synthesis technology, reports CEO archive.twst.com CEO reports on NPS Pharmaceuticals' international presence archive.twst.com Partnering continues to be a very important part of NPS Pharmaceuticals' strategy, reports CEO archive.twst.com CEO outlines the agenda for DURECT for 2001 archive.twst.com CEO reports on DURECT's lead product: DUROS sufentanil archive.twst.com CEO of SangStat Medical looks at the potential for the Thymoglobulin market archive.twst.com CEO reports on the significant advantages of SangStat Medical's RDP58 over existing TNF-alpha inhibitors archive.twst.com CEO describes Telik's current lead compound: the TLK286 archive.twst.com CEO believes that Telik could become an interesting acquisition target archive.twst.com CEO highlights Biogen's competitive advantages archive.twst.com CEO comments on Biogen's current stock price archive.twst.com CEO outlines Microcide Pharmaceuticals' four major partnerships archive.twst.com CEO looks at 3-Dimensional Pharmaceuticals' technology platform for drug discovery archive.twst.com 3-Dimensional Pharmaceuticals' strategy is to license out whatever the company develops, states CEO archive.twst.com CEO reports on Pharsight's global presence archive.twst.com The Medicines Company's CEO comments on the company's current stock valuation archive.twst.com CEO highlights QIAGEN’s competitive advantages archive.twst.com CEO reports on Molecular Devices' lead competitive advantage archive.twst.com CEO reports on Diversa's growth story archive.twst.com President speaks of Genzyme Biosurgery in relation to the competition archive.twst.com CEO looks at Vertex Pharmaceuticals' balance sheet archive.twst.com CEO expects Human Genome Sciences' expenses for R&D to rise archive.twst.com CEO outlines the three greatest opportunities for DIANON Systems archive.twst.com CEO believes Discovery Partners Int'l is extremely well positioned to be a major player in the post-genomic arena archive.twst.com Pharsight has plans for potential partnerships in several areas, states CEO archive.twst.com CEO outlines the agenda for VARIAGENICS for the next 12 to 24 months archive.twst.com Inspire Pharmaceuticals' CEO continues to aggressively patent its technology to maintain the lead in the field of P2Y2 receptors archive.twst.com Esperion Therapeutics aims to focus on accountability, commitment and execution, states CEO archive.twst.com CEO reports on PAREXEL International's global presence archive.twst.com Senior Vice President explains HCA's internal structure archive.twst.com CEO expects Medicis Pharmaceutical to continue to deliver exceptional shareholder value archive.twst.com CEO speaks about the growth opportunities for Biacore International archive.twst.com CEO speaks about the key issues today in the biotech industry that will impact Celgene most directly archive.twst.com President outlines Nexell Therapeutics' strategy for growth archive.twst.com EVP discusses Tularik's sales and marketing strategy archive.twst.com CEO looks at the competitive landscape for Genzyme archive.twst.com Genomic Solutions' CEO speaks about their partnership with PerkinElmer archive.twst.com CEO outlines the agenda for the next 12-24 months for Amylin Pharmaceuticals archive.twst.com Business Development Director reports on SR Pharma's product line in Wall Street Transcript Interview archive.twst.com Analyst rates Professional Detailing a Strong Buy archive.twst.com Analyst highlights ALZA as 'a very well balanced, well rounded company' archive.twst.com Analyst focuses on Bristol-Myers archive.twst.com Analyst has a Buy rating on Applied Biosystems archive.twst.com CEO comments on possible alliances and partnerships for Gene Logic archive.twst.com Caremark Rx' President talks about the biggest opportunity facing the PBM industry archive.twst.com CEO comments on Angiotech Pharmaceuticals' current stock price archive.twst.com CEO speaks about the recent business agreements that Targeted Genetics has completed archive.twst.com PRAECIS PHARMACEUTICALS' CEO comments on the partnering with Amgen archive.twst.com CEO reports on CollaGenex Pharmaceuticals' collaboration with the National Cancer Institute archive.twst.com CEO speaks about Albany Molecular Research's competitive edges archive.twst.com CEO discusses Chronimed's acquisition strategy archive.twst.com First Horizon Pharmaceutical has two new products under development, reports CEO archive.twst.com The focus of SpectRx' current R&D is to develop and launch a continuous glucose monitoring product, states CEO archive.twst.com Gemini Genomics is looking to grow its revenues on the basis of out licensing, states CEO archive.twst.com CEO comments on the competition for EPIX Medical archive.twst.com CEO speaks about the target of Valentis' IL-2 product archive.twst.com CEO talks about Large Scale Biology's business strategy archive.twst.com CEO outlines AtheroGenics' competitive advantages archive.twst.com CEO of Vion Pharmaceuticals envisions TAPET as an “enhancer” archive.twst.com CEO reports on Genaissance Pharmaceuticals' uniqueness archive.twst.com ______________ Healthcare Services CEO highlights the growth opportunities for HEALTHSOUTH archive.twst.com CEO speaks about HealthCentral.com's distribution centers archive.twst.com Illumina will begin performing genotyping services with its technology in early 2001, reports CEO archive.twst.com CEO talks about Humana's new operating model archive.twst.com CEO looks at the competitive landscape for Landacorp archive.twst.com President outlines the competitive advantages of CONMED archive.twst.com CEO believes that the oral insulin program at Emisphere Technologies stands out archive.twst.com CEO commends Trigon Healthcare's management team archive.twst.com CEO outlines MiniMed's short-term goals archive.twst.com CEO looks at the competitive edges for Abgenix archive.twst.com CEO reports on the size of the market that Symyx Technologies is addressing archive.twst.com CEO praises Symphonix Devices' management team archive.twst.com CEO explains why Canada has provided TLC Laser Eye Centers with tremendous opportunities from a technology standpoint archive.twst.com CEO explains why he believes that WellPoint Health Networks is ahead of the competition archive.twst.com CEO looks at the competitive environment for Universal Health Services archive.twst.com Orthofix International's President of North America believes that his company has a lot of upside potential archive.twst.com Accredo Health's CEO comments on the decreasing medication prices, drug prices for elderly people archive.twst.com Edwards Lifesciences' CEO looks at acquisitions as a source of new technology and new ideas archive.twst.com CFO reports on NovaMed Eyecare's growth strategy archive.twst.com According to the CEO of LifePoint Hospitals, the opportunity to grow through acquisition in the rural sector is very positive archive.twst.com American Medical Systems' goal is to continue to introduce innovative products, grow revenues, and improve profitability archive.twst.com According to the CEO of American Medical Systems, incontinence is one of the fastest growing medical problems in the US archive.twst.com CEO highlights iMcKesson's most distinct competitive advantages archive.twst.com CEO is concerned about the health of iMckesson's customer base archive.twst.com CEO of Landacorp commends his top management team archive.twst.com CONMED's long-term goal is really to grow the company internally, reports President archive.twst.com Analyst praises Community Health Systems' performance archive.twst.com MedQuist's President is extremely happy to have Philips as a technology partner archive.twst.com CEO reports on MediChem Life Sciences’ major thrust archive.twst.com President of North America of Orthofix International comments on the company's international presence archive.twst.com CEO reveals the greatest opportunities in the future for Accredo Health archive.twst.com CEO looks at the agenda for Edwards Lifesciences over the next 12-24 months archive.twst.com CFO of NovaMed Eyecare comments on the company’s current stock price archive.twst.com Humana's CEO aims to position the company as the most innovative in its field archive.twst.com CEO comments on LifePoint Hospitals’ management team archive.twst.com Chase H&Q Analyst highlights HCA-The Healthcare Co. archive.twst.com CEO outlines Emisphere Technologies' competitive advantages archive.twst.com CEO aims to continue to back-fill into US markets where HEALTHSOUTH can get the biggest return on its investment archive.twst.com CEO reports on Trigon Healthcare's competitive edges archive.twst.com MiniMed's objective is to combine pumps and sensors to create automatic delivery of insulin for diabetes, states CEO archive.twst.com CEO talks about Abgenix' XenoMouse™ technology archive.twst.com Symyx Technologies' focus is on building a rapidly growing, profitable business, states CEO archive.twst.com CEO of HealthCentral.com is trying to create 'a super health store' archive.twst.com Symphonix Devices' CEO plans on emphasizing organic growth within the company archive.twst.com CEO of TLC Laser Eye Centers discusses the extreme pricing competition in the laser vision correction market archive.twst.com Illumina’s mission is to develop next-generation tools for the large-scale analysis of genetic variation and function, states CEO archive.twst.com CEO highlights WellPoint Health Networks' competitive advantages archive.twst.com CEO speaks about the growth opportunities for Medarex archive.twst.com CEO reports on Matrix Pharmaceutical's strategic plan archive.twst.com Universal Health Services' CEO details the company's strategy of locating in fast-growing markets archive.twst.com CEO believes Packard BioScience is going to benefit from an enormous growth in functional genomics archive.twst.com